Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961027 | 0.91 | HSP90AB1 (0.58) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL28118610 | 0.91 | HSP90AB1 (0.58) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL7069525 | 0.90 | HSP90AB1 (0.56) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL7073645 | 0.88 | HSP90AB1 (0.54) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL31075998 | 0.88 | HSP90AB1 (0.54) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL1525224 | 0.88 | HSP90AB1 (0.54) | HSP90AB1ALDH1A1GAAGFERKMT2A | |
| SCHEMBL5283381 | 0.87 | THRA (0.52) | HSP90AB1TRPV1THRBTHRAPPARG | |
| SCHEMBL1302419 | 0.85 | HSP90AB1 (0.51) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL20599232 | 0.85 | HSP90AB1 (0.51) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL12678868 | 0.85 | HSP90AB1 (0.58) | HSP90AB1ALDH1A1GAAGFERCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1862450-A2 | Novel compounds | KARO BIO AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1537073-B1 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KAROBIO AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | disclosed |
| US-20060135614-A1 | Novel compounds | NORIN, THOMAS ANDERS WILSON (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1509188-A4 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KAROBIO AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1537073-A2 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| EP-1509188-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2005-03-02 | — | — | EP | disclosed |
| EP-1143948-A3 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002043648-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044120-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR III | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1185229-A1 | METHOD OF TREATING HAIR LOSS | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1143948-A2 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1102739-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000072811-A1 | METHOD OF TREATING HAIR LOSS | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000007972-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999063976-A2 | LIVER-SELECTIVE GLUCOCORTICOID ANTAGONIST FOR TREATING DIABETES | KARO BIO AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | HSP90AB1 2019/4885ALDH1A1 2909/4885GAA 4699/4885 |
| US-20060135614-A1 | Novel compounds | THRB, TSHR, THRA | HSP90AB1 731/4885ALDH1A1 1777/4885GAA 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.